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SHORT COMMNUNICATION
A phase II study of carboplatin and vinorelbine as second-line treatment
for advanced breast cancer
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Slmnerap Forty-one patients with advanced breast cancer were gven carboplatin and vinorelbine as second-
line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxcicity was
the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our
regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.
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Although antracycline-including chemotherapy induces res-
ponses in 50-70% of patients with advanced breast cancer,
cure is never achieved. Therefore, most patients require
second-line treatment whose overall response rate does not
exceed 30%, with no definite impact on survival (Henderson,
1991).
The identification of new antiproliferative agents which
lack cross-resistance with the drugs commonly used as first-
line therapy continues to be a major area of research (Lipp-
man, 1993). Carboplatin, a cisplatin analogue that is
significantly less nephrotoxic and neurotoxic than cisplatin
itself (O'Brien et al., 1993), has attractive features as a drug
for the treatment of breast cancer because it is not associated
with serious organ toxicities, apart from bone marrow supp-
ression. Relatively few phase II studies of carboplatim in
advanced breast cancer have been published; in all of them a
relationship between activity and lack of previous treatment
has been reported (Kolaric and Vukas, 1991; Martin et al.,
1992).
Vinorelbine (VRL, Navelbine; Pierre Fabre Medicanment,
Boulogne, France) is a new semisynthetic vinca alkaloid that
differs from the others by a substitution that affects the
catharanthine moiety and not the vindoline moiety of the
molecule (Potier, 1989). Several phase II studies of single-
agent VRL as first-line treatment in advanced breast cancer
have been conducted (Canobbio et al., 1989; Lluch et al..
1992; Fumoleou et al., 1993; Romero et al., 1994; Twelves et
al., 1994), with response rates ranging from 41% to 60%,
good tolerance, minor neurotoxicity and rapidly reversible
leucopenia. Furthermore, synergy and good tolerance have
been observed when vinorelbine is used in combination with
platinum compounds (Cros. 1989; Crawford and O'Rourke,
1994).
We report our experience with a combination of carbo-
platin and vinorelbine in 41 pretreated patients with
advanced breast cancer.
Patients and methods
Patients with advanced breast cancer who had progressed
after first line anthracycine-based chemotherapy entered the
study. A normal initial blood count (leucocyte >4000 ml-',
platelets > 100 000 ml-') was required. Further eligibility
criteria were: presence of measurable lesions, creatiine
<2 mg dl1. bilirubin <2 mg dl-'. left ventricular ejection
fraction > 50%. age less than 75 years, Eastern Cooperative
Oncology Group (ECOG) performance status of 2 or less,
and absence of other concomitant cancers. Informed consent
was obtained from each patient.
Treatment consisted of carboplatin administered int-
ravenously (i.v.) over 1 h at the dose of 250 mg m-2 on day 1
of the cycle and vinorelbine administered at the dose of
30 mg m- i.v. in 500 ml of saline solution over 1 h on days 1
and 8. Courses were repeated every 28 days. All patients
received intravenous granisetron as antiemetic coverage. The
VRL dose on the eighth day was administered only in the
presence of a leucocyte count > 3000 ml'- and platelet count
>120000ml-1. In the case of leucocyte counts less than
2000 ml-' and/or platelet count less than 100 000 ml'- before
the start of each course, treatment was delayed for 1 week
and granulocyte colony-stimulating factor (G-CSF) was
administered for 4 days at a dose of 5 jig kg-' sub-
cutaneously in order to permit recovery from myelosuppres-
sion. In the case of grade III or worse neurotoxicity. treat-
ment was delayed until recovery.
Patients were considered evaluable for response assessment
and for toxicity after a minimum of two courses of
chemotherapy; however, patients who were lost to follow-up
or who discontinued treatment early because of severe toxic
effects were included in the analysis, which was based on
intent to treat. Response and toxicity were assessed according
to standard World Health Organization (WHO) cnrteria
(1979). In particular, complete remission (CR) in bone was
defined as a recalcification of all lytic osseous lesions and
disappearance of all abnormal uptake areas on a bone scan.
Partial remission (PR) in bone was considered as an improve-
ment or stabilisation of radiographic assessment of disease
with decrease in bone pain and improvement in performance
status. Each response at any site had to be verified on two
occasions at least 1 month apart. The duration of response
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1995was measured from the onset of the best response. Survival
was alIculated from the on-study date. The Kaplan-Meier
(1958) method was used to caculate the probability of sur-
vival as a function of time.
Res
From October 1991 to April 1994, 41 patients entered the
study and were assssable for response and toxcity. All of
the patients had one course of anthracyaine-based
chemotherapy for m atic disease. The median time from
treatment with first-ine chemotherapy and introdction of
our combination was 15 months. No patients had receved
previous hormone therapy for metastases. Dominant sites of
metastasis were viscera in 46% of cases, skeleton in 22% and
soft tissue/lymph nodes in 32% of the patients; five patients
had only bone disease. Patient cactrstics are deailed
Table I.
Three patients achieved a complete response (7%) and 14
patients achieved a partial response (34%), giving an overall
objective response rate of 41% (95% confidence interval
26-56%). Four additional patients had a stable disease
(10%), while the rZmaining 20 patients (49%) were con-
sidered unresponsive. Table II summanse response rates
according to tumour site. The most exciting complete res-
ponse was observed in a 34-year-old woman who had exten-
sive liver metastases and had progresed after three courses
of first-line chemotherapy. This complete remission is pres-
ently maintained after 12 months follow-up. The two other
complete responses were observed in patients with soft tissue
involvement. Six partial responses were observed in 15
patients with bone metastases. In all these patients lesions
were lytic in nature. Median duration of response was 7
months (range 3-15+). At a median follow-up of 20
months, median survival was 16 months for responders and 8
months for non-responders.
A total of 140 courses of chemotherapy have been
administered thus far (median 3.4, range 1-6). No treatment-
Table I Patient characteristics
Characteristic No. ofpatients %
Evaluable (median age 55 years, 41 100
range 26-74 years)
Performance status
0-1 25 61
2 16 39
Menopausal status
Preperimenopausal 28 68
Post-menopausal 13 32
Prior adjuvant CMF chemotherapy
Yes 22 54
No 19 46
Prior adjuvant Tamoxifen hormone therapy
Yes 13 32
No 28 68
First-ine chemotherapy for metastasis
HD-EPI 25 61
FEC 16 39
Sites of disease
Viscera 19 46
Bone 15 36
Soft tissue 14 34
Lymph nodes 13 32
Number of sites of disease
1 22 54
2 18 44
3 1 2
Dominant sites of disease
V-iscera 19 46
Skeleton 9 22
Soft tissue/lymph nodes 13 32
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related deaths have occurred. The most frequently observed
toxic effect was leucopenia; grade III-IV white blood cell
toxicity, in fact, ocurred in 19 patients (46%), causing
delays in the administration of chemotherapy in 41 courses
and omission of the second VRL dose in 19 courses. In all
cases in which treatment was delayed, G-CSF was
administerd and induced normalisaton of haematological
parameters within 1 week. Grade Ill thrombocytopenia
occurred in six cases (15%) and was always associated with
at least grade H leucopenia; red blood cell toxicity reached
grade HI in only one case (2%). In spite of the orrce of
frequent severe myelosuppression, life-threatening infections
never occurred. Peripheral neuropathy of grade I-H was
recorded in 18 cases (44%), but was always completey rever-
sible and never required dose reductions or treatment delays.
Chemical phklbitis at the infusion site of grade I-H
(Fumoleau et al., 1993) was a quite frequent toxic effect;
VRL administration in 125 ml of normal saline over 20min
substantially reduced its idence in the later patients. One
patient had a pulmonary embolus after the first course, but
its association with treatment is questionable. Toxic effects
are smmarised in Table Ill.
Despite significant improvements in medical treatment in the
last 20 years, metastatic breast cancer is still considered to be
an incurable disease. While novel biological therapeutic
strategies targeted to factors spefically involved in tumour
progression and metastasis are being developed (Lippman,
1993), investigational efforts are presendy directed to the
identification of new active agents with a higher therapeutic
index.
Carboplatin has attractive features as a drug for the treat-
ment of advanced breast cancer, because of its significntly
lower nephrotoxicity and neurotoxicity compared with the
parent compound. However, in the phase H studies of car-
boplatin in advanced breast cancer published so far, activity
has been demonstrated mainly in untreated patients (Kolaric
and Vukas, 1991; Martin et al., 1992). Vinorelbine is a novel
vinca alkaloid (Potier et al., 1989) that is attractive because
of the possible lack of cross-resistance with other drugs
which are active against breast cancer (Henderson, 1991) and
because of its low neurotoxicity, which is presumably related
to its selctive affinity for mitotic tubulin and tubulin-
associated proteins (Potier et al., 1989), with relative sparing
of axonal microtubuks (Fellons et al., 1989).
In our study 17 of 41 patients (41%) achieved a major
objective response with the combination of carboplatin and
Tabie Response rates acording to tumour site
Twnour site (mmer) CR + PR (nwnber)
liver (10) 1+ 2
Lung (9) 0+ 3
Bone (15) 0+ 6
Sof tissues (14) 2+ 5
Lymph nodes (13) 0+7
Table m Toxiatya
WHO Grade
0 1 2 3 4 Total
Haemoglobin 12 18 10 1 0 29
Leucocytes 3 9 10 18 1 38
Platelets 6 14 15 6 0 35
Infection 24 11 6 0 0 17
Nauseavomiting 24 11 6 0 0 17
Alopecia 20 11 6 4 0 21
Neurotoxicity 23 14 4 0 0 18
Phlebitis 21 12 6 2 0 20
Asthenia 34 6 1 0 0 7
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vinorelbine. Three complete responses were observed, one of
which was achieved in a young woman with extensive liver
metastases. The median duration of response in our Patient
eries was 7 months, and the median overall survival for
responding patients was 16 months.
As expected, haematological toxicity was the most com-
monly observed toxic effect in our study. In fact, grade
m-IV myelotoxicty was observed m 46% of the patients
and frequently required delays in drug adminstration. How-
ever, infective compliations were rare and no treatment-
related deaths were observed.
Other toxic effects were mild. In particular, peripheral
neuropathy was infrequent and compltWy revsible. These
rults compare favourably with those reported by other
studies, in which vinorelbine has been used, alone or in
combination, in pretreated patients with advanced beast
cancer. In fact, Gasparini et al. (1994) have recntly reported
a 36% objective response rate in 67 patients with previously
treated breast cancer in n vinorelbine at the dose of
20mgm2 weekly. egan et al. (1994) have treated 100
patients with refractory advanced breast cancer miing
vinorelbine at the dose of 30mgm 2 weekly and have
reported an overall objective response rate of 16% with a
median response duration of 5 months. Scheithauer et al.
(1993) have reported an overall objective resonse rate of
35% in 34 patients with metastatic breast cancer refractory
to first-line chemotherapy using a combination ofvinorelbn
(30mgm 2 every 3 weeks) and mitomycin C (15mgm-2
every 6 weeks). To date, only one study has been pubfished
in which carboplatin has been evaluated, combined with
etoposide, in patients with pretreated metastatic breast
cancer. This combination resulted in a very low partial res-
ponse rate (13%), which caused the early interruption of the
trial at 23 patients (Barker et al., 1993).
We believe that the results of our study justify the use of
our combination in the salvage treatment of advanced breast
cancer, although quality of life, which is to be considered an
important end point in such trials (Porzsolt and Tannock,
1993), should be more properly a
We beieve that some important points need to be clarified
in order to improve treatment results further:
(1) The best dosage and schedule of administration of
vinorelbine has to be identified; in particular, the
hypothesis of the better therapeutic index achieved by the
continuous infusion of this cell-cycle phase-specific drug
has to be verified (Toussaint et al., 1994).
(2)The possibility of a more correct calculation of carbo-
platin dosage, according to Calvert (1989) criteria, is to be
considered; we are induced to believe that the use of a
pharmacokinetically derived carboplatin dose could con-
tribute to improve the therapeutic index of the drug.
(3)Given the h incidence of myekosupression as dose-
lmiting toxicity observed with our regImen, ftr inves-
tigations into the optmal schedulng of these agents with
G-CSF are to be performed in order to eventually allow
either further dose escalation or the addition of other
active agents to this regi-en.
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